Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Feb;32(2):224–230. doi: 10.1128/aac.32.2.224

Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.

F G Hayden 1, D L Kaiser 1, J K Albrecht 1
PMCID: PMC172139  PMID: 2834996

Abstract

In a double-blind, placebo-controlled study, patients with naturally occurring common colds of less than or equal to 48 h duration were randomly assigned to receive nasal sprays of recombinant alfa-2b interferon at 10 or 20 MU/day or placebo four times per day for 5 days. The 10-MU (n = 74), 20-MU (n = 74), and placebo (n = 72) groups had comparable frequencies of documented rhinovirus colds (50 to 65%) and mean durations of pretreatment symptoms (26 to 27 h). The median duration of colds tended to be longer in the 20-MU group (10 days) than the 10-MU group (8 days) or placebo group (8 days) (P = 0.06). In those with proven rhinovirus colds treated within 24 h, the median duration was significantly longer in the 20-MU group (9 days) than in the placebo group (6 days). No differences favoring interferon treatment were found in respiratory symptom scores or resolution of specific symptoms. On days 5 and 7, nasal washings from compliant subjects with proven rhinovirus colds yielded rhinoviruses more often in placebo (47 and 48%, respectively) than in interferon (15 and 16%, respectively) recipients (P less than 0.02), but no differences in new respiratory illness occurrence were observed in household contacts. Interferon recipients had significantly higher frequencies of blood in nasal mucus (16 to 18%) than did placebo recipients (4%) during treatment. Antibiotics for presumed secondary infections were given more often in the 20-MU group (11%) than in the placebo group (0%) (P less than 0.01). Nasal sprays of recombinant alfa-2b interferon were not an effective treatment for natural colds and were associated with toxicity.

Full text

PDF
224

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Douglas R. M., Albrecht J. K., Miles H. B., Moore B. W., Read R., Worswick D. A., Woodward A. J. Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection. J Infect Dis. 1985 Apr;151(4):731–736. doi: 10.1093/infdis/151.4.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Douglas R. M., Moore B. W., Miles H. B., Davies L. M., Graham N. M., Ryan P., Worswick D. A., Albrecht J. K. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med. 1986 Jan 9;314(2):65–70. doi: 10.1056/NEJM198601093140201. [DOI] [PubMed] [Google Scholar]
  3. Farr B. M., Gwaltney J. M., Jr, Adams K. F., Hayden F. G. Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother. 1984 Jul;26(1):31–34. doi: 10.1128/aac.26.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hayden F. G., Albrecht J. K., Kaiser D. L., Gwaltney J. M., Jr Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med. 1986 Jan 9;314(2):71–75. doi: 10.1056/NEJM198601093140202. [DOI] [PubMed] [Google Scholar]
  5. Hayden F. G., Gwaltney J. M., Jr Anti-interferon antibody increases rhinovirus isolation rates from nasal wash specimens containing interferon-alpha 2. Antiviral Res. 1983 Mar;3(1):67–71. doi: 10.1016/0166-3542(83)90016-5. [DOI] [PubMed] [Google Scholar]
  6. Hayden F. G., Gwaltney J. M., Jr Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis. 1983 Sep;148(3):543–550. doi: 10.1093/infdis/148.3.543. [DOI] [PubMed] [Google Scholar]
  7. Hayden F. G., Gwaltney J. M., Jr Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. J Infect Dis. 1984 Aug;150(2):174–180. doi: 10.1093/infdis/150.2.174. [DOI] [PubMed] [Google Scholar]
  8. Hayden F. G., Mills S. E., Johns M. E. Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2. J Infect Dis. 1983 Nov;148(5):914–921. doi: 10.1093/infdis/148.5.914. [DOI] [PubMed] [Google Scholar]
  9. Hayden F. G., Winther B., Donowitz G. R., Mills S. E., Innes D. J. Human nasal mucosal responses to topically applied recombinant leukocyte A interferon. J Infect Dis. 1987 Jul;156(1):64–72. doi: 10.1093/infdis/156.1.64. [DOI] [PubMed] [Google Scholar]
  10. Monto A. S., Shope T. C., Schwartz S. A., Albrecht J. K. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection. J Infect Dis. 1986 Jul;154(1):128–133. doi: 10.1093/infdis/154.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Phillpotts R. J. Antibody to human leucocyte interferon may enhance the frequency of rhinovirus isolation. Arch Virol. 1983;75(1-2):143–145. doi: 10.1007/BF01314135. [DOI] [PubMed] [Google Scholar]
  12. Scott G. M., Phillpotts R. J., Wallace J., Gauci C. L., Greiner J., Tyrrell D. A. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet. 1982 Jul 24;2(8291):186–188. doi: 10.1016/s0140-6736(82)91031-5. [DOI] [PubMed] [Google Scholar]
  13. Wilson R., Alton E., Rutman A., Higgins P., Al Nakib W., Geddes D. M., Tyrrell D. A., Cole P. J. Upper respiratory tract viral infection and mucociliary clearance. Eur J Respir Dis. 1987 May;70(5):272–279. [PubMed] [Google Scholar]
  14. Yeh T. J., McBride P. T., Overall J. C., Jr, Green J. A. Automated, quantitative cytopathic effect reduction assay for interferon. J Clin Microbiol. 1982 Aug;16(2):413–415. doi: 10.1128/jcm.16.2.413-415.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES